Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals (Nasdaq: VRCA) will present new Phase 2 data on VP-315, an oncolytic peptide for basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, November 5–9, 2025, in National Harbor, Maryland.
The company will deliver an oral presentation (Abstract 529) on November 6, 2025 during Concurrent Session 205b with a 12:46–12:54 p.m. ET presentation slot exploring local immune activation in the tumor microenvironment 12 weeks after VP-315. A companion poster with the same exploratory analysis will also be presented. The abstract will be posted on the SITC website on or about November 4, 2025 at 9:00 a.m. ET.
Verrica Pharmaceuticals (NASDAQ:VRCA) announced that its development partner, Torii Pharmaceutical, has received approval from Japan's Ministry of Health for YCANTH® (TO-208) to treat Molluscum Contagiosum. This approval triggers a $10 million milestone payment to Verrica, strengthening its balance sheet with non-dilutive capital.
The approval follows positive Phase 3 trial results in Japan, where YCANTH demonstrated statistically significant efficacy in achieving complete clearance of molluscum lesions compared to placebo. Verrica maintains global rights to YCANTH outside Japan and plans to initiate a global Phase 3 program for common warts treatment by the end of 2025.
Verrica Pharmaceuticals (NASDAQ:VRCA), a dermatology therapeutics company, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will present on Monday, September 8, 2025, at 9:30 am ET.
Investors can access the presentation through a live webcast available on Verrica's website, with a replay available for 90 days following the event.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported strong Q2 2025 financial results with total revenue of $12.7 million, including $4.5 million from YCANTH® sales and $8.0 million in milestone revenue from Torii Pharmaceutical. YCANTH showed impressive growth with 13,434 dispensed applicator units, representing a 32.8% sequential increase from Q1 2025.
The company achieved a net income of $0.2 million ($0.02 per share) compared to a net loss of $17.2 million in Q2 2024. Verrica completed a successful End of Phase 2 Meeting for VP-315 in basal cell carcinoma and is preparing for Phase 3 while exploring non-dilutive financing options. The company expects an additional $10 million milestone payment upon Japanese regulatory approval of YCANTH by year-end 2025.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, will host a conference call and webcast on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update.
Participants can join via telephone using 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with conference ID: VERRICA. The webcast will be available on the company's investor relations website and archived for 90 days.
Verrica Pharmaceuticals (NASDAQ:VRCA) reported significant growth in YCANTH® dispensed applicator units for Q2 2025, achieving 13,434 units, representing a 32.8% sequential increase from Q1 2025. This growth rate nearly doubled the previous quarter's 16.7% sequential growth.
The company received an $8 million milestone payment from Japanese partner Torii Pharmaceutical for initiating a global Phase 3 program in common warts. Additional potential includes a $10 million milestone payment upon YCANTH's approval in Japan for molluscum. The company also highlighted amendments to its Credit Agreement with OrbiMed and progress with VP-315 for basal cell carcinoma treatment.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced a significant amendment to its Collaboration and License Agreement with Torii Pharmaceutical for launching a global Phase 3 clinical trial of YCANTH® to treat common warts. The company will receive an $8 million milestone payment in July 2025 for initiating the study, and an additional $10 million milestone payment upon YCANTH's approval for molluscum contagiosum in Japan, expected by end of 2025.
The agreement includes Torii funding the first $40 million of out-of-pocket costs for the global study, covering approximately 90% of the current clinical budget. The study targets common warts, which affects 22 million patients in the United States alone, with no current FDA-approved prescription therapies. Verrica plans to dose the first patient in the U.S. Phase 3 trial in Q4 2025.
Under the amended agreement, Verrica maintains ownership of global rights to YCANTH for all indications outside Japan. The companies will split the Phase 3 program costs 50/50, with Verrica repaying its portion through offsets against future royalties and transfer price payments from Torii. Additionally, Verrica will initiate a manufacturing transfer to Torii for YCANTH applicators for the Japanese market.
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation on Wednesday, June 4, 2025, at 4:20 pm ET.
The event will be accessible via live webcast through the company's website and a dedicated link. A replay will be available for 90 days following the presentation in the Investors/Presentations & Events section of www.verrica.com.
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, has scheduled its Q1 2025 earnings conference call and webcast for May 13, 2025, at 4:30 p.m. ET. The company will discuss financial results for the quarter ending March 31, 2025, and provide corporate updates.
Participants can join via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) using conference ID: VERRICA. The webcast will be accessible through Verrica's investor relations website and will remain archived for 90 days after the event.